Oct 03, 2023 / 04:15PM GMT
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. We'll get started here as people kind of pick up their lunches and come in, but good afternoon. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. And I have the pleasure of welcoming Masoud Toloue, President and CEO of Quanterix to my right; and Joel Braunstein, Co-Founder and CEO of C2N on further to my right. These are 2 companies which are at the forefront of developing commercializing blood-based biomarker testing for Alzheimer's disease. Masoud and Joel, welcome.
Masoud Toloue - Quanterix Corporation - President, CEO & Director
Hey, Matt.
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
So this is a discussion that I've been selfishly looking forward to for some time. Last week, my team published a deep dive on blood biomarker testing for Alzheimer's, where we developed a market model for Alzheimer's testing outlining a potential
Quanterix Corp at Goldman Sachs Alzheimer's Disease Day Transcript
Oct 03, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers